CVRx, Inc. develops implantable technology for the treatment of patients with high blood pressure / hypertension and heart failure.
| Revenue (TTM) | $61.19M |
| Gross Profit (TTM) | $53.18M |
| EBITDA | $-47.84M |
| Operating Margin | -82.90% |
| Return on Equity | -133.50% |
| Return on Assets | -28.70% |
| Revenue/Share (TTM) | $2.33 |
| Book Value | $0.75 |
| Price-to-Book | 4.14 |
| Price-to-Sales (TTM) | 1.20 |
| EV/Revenue | 1.265 |
| EV/EBITDA | -1.31 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 15.60% |
| Shares Outstanding | $26.64M |
| Float | $18.50M |
| % Insiders | 9.71% |
| % Institutions | 65.85% |
Volatility is currently contracting
Boston, Massachusetts--(Newsfile Corp. - August 18, 2026) - Block & Leviton is investigating CVRx, Inc. (NASDAQ: CVRX) for potential securities law violations. Investors who have lost money in their CVRx, Inc. investment should contact the firm to learn more about how they might recover those losses.
Boston, Massachusetts--(Newsfile Corp. - August 13, 2026) - Block & Leviton is investigating CVRx, Inc. (NASDAQ: CVRX) for potential securities law violations. Investors who have lost money in their CVRx, Inc. investment should contact the firm to learn more about how they might recover those losses.
CVRx NASDAQ: CVRX outlined its efforts to expand adoption of its Barostim therapy for heart failure patients, emphasizing sales-force execution, payer coverage progress and a large post-market clinical trial during Canaccord Genuity's 46th Annual Growth Conference.
CVRx, Inc. (CVRX) Q2 2026 Earnings Call Transcript
CVRx (CVRX) came out with a quarterly loss of $0.53 per share versus the Zacks Consensus Estimate of a loss of $0.52. This compares to a loss of $0.57 per share a year ago.
MINNEAPOLIS, Aug. 06, 2026 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced its financial and operating results for the second quarter of 2026.
MINNEAPOLIS, July 28, 2026 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, announced today that the management team will present at Canaccord Genuity's 46th Annual Growth Conference in Boston on Tuesday, August 11, 2026. The Company's presentation will begin at 1:00 p.m. (ET).
MINNEAPOLIS, July 23, 2026 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced that it plans to release second quarter 2026 financial and operating results after market close on Thursday, August 6, 2026. The Company will host a conference call to review its results at 4:30 p.m. Eastern Time the same day. A live webcast of the investor conference call will be available online at the investor relations page of the Company's website at ir.cvrx.com. To listen to the conference call on your telephone, please dial 1- 877-704-4453 for U.S. callers, or 1-201-389-0920 for international callers, approximately ten minutes prior to the start time. About CVRx, Inc. CVRx is a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases. Barostim™ is the first medical technology approved by FDA that uses neuromodulation to improve the symptoms of patients with heart failure. Barostim is an implantable device that delivers electrical pulses to baroreceptors located in the wall of the carotid artery. The therapy is designed to restore balance to the autonomic nervous system and thereby reduce the symptoms of heart failure. Barostim received the FDA Breakthrough Device designation and is FDA-approved for use in heart failure patients in the U.S. It has been certified as compliant with the EU Medical Device Regulation (MDR) and holds CE Mark for heart failure and resistant hypertension in the European Economic Area. To learn more about Barostim, visit www.cvrx.com. Investor Contact:Mark Klausner or Mike VallieICR Healthcare443-213-0501 ir@cvrx.com Media Contact:Emily Meyers CVRx, Inc. 763-416-2853 emeyers@cvrx.com
CVRx (CVRX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
CVRx, Inc. (CVRX) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on CVRX and any ticker you trade — then tracks every position and per-strategy win rate.
